

Francesco Pisani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10197015/publications.pdf>

Version: 2024-02-01

51
papers

2,864
citations

361413

20
h-index

189892

50
g-index

53
all docs

53
docs citations

53
times ranked

3716
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	27.0	697
2	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	4.6	442
3	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
4	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
5	Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2077-2084.	1.6	246
6	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	1.4	87
7	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015, 29, 689-695.	7.2	75
8	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
9	Cyclosporin-induced inhibition of mTOR pathway enables stress-induced autophagy. <i>EMBO Journal</i> , 2015, 34, 1214-1230.	7.8	66
10	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
11	Arrest of Replication Fork Progression at Sites of Topoisomerase II-Mediated DNA Cleavage in Human Leukemia CEM Cells Incubated with VM-26. <i>Biochemistry</i> , 1997, 36, 5739-5748.	2.5	31
12	Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 70-73.	1.5	29
13	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	1.6	29
14	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. <i>Bone Marrow Transplantation</i> , 2017, 52, 154-156.	2.4	27
15	IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 17.	8.6	25
16	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
17	Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. <i>Haematologica</i> , 2019, 104, 82-92.	3.5	24
18	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. <i>British Journal of Haematology</i> , 2013, 160, 673-679.	2.5	23

#	ARTICLE	IF	CITATIONS
19	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α -Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. <i>Integrative Cancer Therapies</i> , 2018, 17, 1115-1124.	2.0	23
20	Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. <i>Leukemia</i> , 2022, 36, 588-590.	7.2	23
21	Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study. <i>World Journal of Transplantation</i> , 2015, 5, 129.	1.6	22
22	Follicular dendritic cell sarcoma of the neck: Report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 33.	8.6	17
23	Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study. <i>Transplant Infectious Disease</i> , 2014, 16, 1032-1038.	1.7	17
24	Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. <i>Journal of Infection</i> , 2016, 72, 265-268.	3.3	17
25	Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. <i>Cancer</i> , 2012, 118, 5544-5549.	4.1	15
26	Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant. <i>Chemotherapy</i> , 2017, 62, 58-61.	1.6	15
27	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1373.	4.1	15
28	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. <i>Leukemia Research</i> , 1996, 20, 535-549.	0.8	14
29	Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1041-1048.	1.8	14
30	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
31	Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience. <i>British Journal of Haematology</i> , 2016, 172, 980-982.	2.5	11
32	Comparison between biosimilar filgrastim vs other granulocyte colony stimulating factor formulations (originator filgrastim, pegfilgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. <i>British Journal of Haematology</i> , 2015, 169, 293-296.	2.5	10
33	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5616-5630.	5.2	10
34	Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?. <i>Journal of Bone Oncology</i> , 2021, 26, 100338.	2.4	9
35	Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 35.	8.6	8
36	Biosimilar filgrastim (Zarzio [®]) vs. lenograstim (Myelostim [®]) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 489-492.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 17.	5.0	7
38	The Effect of Docosahexaenoic Acid and Î±-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541988858.	2.0	7
39	FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 16.	8.6	6
40	The predictive value of <i>Aspergillus</i> PCR testing on bronchoalveolar lavage fluid for early diagnosis of invasive pulmonary aspergillosis in hematologic patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2943-2946.	1.3	6
41	Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. <i>World Journal of Hepatology</i> , 2016, 8, 1244.	2.0	6
42	Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 37.	8.6	5
43	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020, 10, 848.	2.8	5
44	Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge. <i>Case Reports in Oncology</i> , 2014, 7, 277-284.	0.7	4
45	Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 49.	8.6	4
46	Lenograstim 5 Âµg/kg is not superior to biosimilar filgrastim 10 Âµg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. <i>Transfusion</i> , 2018, 58, 1143-1148.	1.6	4
47	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1051-1054.	2.4	4
48	Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. <i>Clinical Neuropharmacology</i> , 2019, 42, 167-171.	0.7	2
49	Coexistence of three variants of cutaneous mastocytosis as the presenting sign of systemic mastocytosis with somatic c-Kit D816V point mutation. <i>International Journal of Dermatology</i> , 2014, 53, 1265-1268.	1.0	1
50	Follow-up of IgD-Î± multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report. <i>Oncology Letters</i> , 2016, 12, 1884-1888.	1.8	1
51	Interference by biological anti-cancer drugs in electrophoretic and immunofixation techniques. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e297-9.	2.3	0